Lancet Regional Health-Europe最新文献

{"title":"Associations between degree of food processing and all-cause and cause-specific mortality: a multicentre prospective cohort analysis in 9 European countries","authors":"Esther M. González-Gil ,&nbsp;Michèle Matta ,&nbsp;Fernanda Morales Berstein ,&nbsp;Manon Cairat ,&nbsp;Geneviève Nicolas ,&nbsp;Jessica Blanco ,&nbsp;Nathalie Kliemann ,&nbsp;Renata Bertazzi Levy ,&nbsp;Fernanda Rauber ,&nbsp;Inarie Jacobs ,&nbsp;Aline Al Nahas ,&nbsp;Emine Koc Cakmak ,&nbsp;Eszter P. Vamos ,&nbsp;Kiara Chang ,&nbsp;Sahar G. Yammine ,&nbsp;Christopher Millett ,&nbsp;Mathilde Touvier ,&nbsp;Maria Gabriela Matias Pinho ,&nbsp;Konstantinos K. Tsilidis ,&nbsp;Alicia K. Heath ,&nbsp;Inge Huybrechts","doi":"10.1016/j.lanepe.2024.101208","DOIUrl":"10.1016/j.lanepe.2024.101208","url":null,"abstract":"<div><h3>Background</h3><div>Ultra-processed food (UPF) consumption has been linked with higher risk of mortality. This multi-centre study investigated associations between food intake by degree of processing, using the Nova classification, and all-cause and cause-specific mortality.</div></div><div><h3>Methods</h3><div>This study analyzed data from the European Prospective Investigation into Cancer and Nutrition. All-cause mortality and cause-specific mortality due to cancer, circulatory diseases, digestive diseases, Parkinson’s disease, and Alzheimer’s disease served as endpoints. Hazard ratios (HRs) and 95% CIs were estimated using multivariable Cox proportional hazards regression models. Substitution analyses were also performed.</div></div><div><h3>Findings</h3><div>Overall, 428,728 (71.7% female) participants were included in the analysis and 40,016 deaths were documented after 15.9 years of follow-up. UPFs (in percentage grams per day [g/d]) were positively associated with all-cause mortality (HRs per 1-SD: 1.04; 95% CI: 1.02,1.05), as well as mortality from circulatory diseases (1.09; 95% CI: 1.07,1.12), cerebrovascular disease (1.11; 95% CI: 1.05,1.17), ischemic heart disease (1.10; 95% CI: 1.06,1.15), digestive diseases (1.12; 95% CI: 1.05,1.20), and Parkinson’s disease (1.23; 95% CI: 1.06,1.42). No associations were found between UPFs and mortality from cancer or Alzheimer’s disease. Replacing processed and UPFs with unprocessed/minimally processed foods was associated with lower mortality risk.</div></div><div><h3>Interpretation</h3><div>In this pan-European analysis, higher UPF consumption was associated with greater mortality from circulatory diseases, digestive diseases, and Parkinson’s disease. The results support growing evidence that higher consumption of UPFs and lower consumption of unprocessed foods may have a negative impact on health.</div></div><div><h3>Funding</h3><div><span>l’Institut National du Cancer</span>, and <span>World Cancer Research Fund International</span>.</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"50 ","pages":"Article 101208"},"PeriodicalIF":13.6,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11764076/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143048670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dynamic association of antimicrobial resistance in urinary isolates of Escherichia coli and Klebsiella pneumoniae between primary care and hospital settings in the Netherlands (2008–2020): a population-based study","authors":"Evelyn Pamela Martínez ,&nbsp;Annelies Verbon ,&nbsp;Annelot F. Schoffelen ,&nbsp;Wieke Altorf-van der Kuil ,&nbsp;Joost van Rosmalen","doi":"10.1016/j.lanepe.2024.101197","DOIUrl":"10.1016/j.lanepe.2024.101197","url":null,"abstract":"<div><h3>Background</h3><div>It is unclear whether changes in antimicrobial resistance (AMR) in primary care influence AMR in hospital settings. Therefore, we investigated the dynamic association of AMR between primary care and hospitals.</div></div><div><h3>Methods</h3><div>We studied resistance percentages of <em>Escherichia coli</em> and <em>Klebsiella pneumoniae</em> isolates to co-amoxiclav, ciprofloxacin, fosfomycin, nitrofurantoin and trimethoprim submitted by primary care, hospital outpatient and hospital inpatient settings to the Dutch National AMR surveillance network (ISIS-AR) from 2008 to 2020. For each bacterium–antibiotic combination, we first conducted multivariable logistic regressions to calculate AMR odds ratios (ORs) by month and healthcare setting, adjusted for patient-related factors and a time term. Second, multiple time series analysis was done using vector autoregressive models including the (log) ORs for each bacterium–antibiotic combination. Models were interpreted by impulse response functions and Granger-causality tests.</div></div><div><h3>Findings</h3><div>The main AMR association was unidirectional from primary care to hospital settings with Granger-causality p-values between &lt;0.0001 and 0.029. Depending on the bacterium–antibiotic combination, a 1% increase of AMR in <em>E. coli</em> and <em>K. pneumoniae</em> in primary care leads to an increase of AMR in hospital settings ranging from 0.10% to 0.40%. For ciprofloxacin resistance in <em>K. pneumoniae,</em> we found significant bidirectional associations between all healthcare settings with Granger-causality p-values between &lt;0.0001 and 0.0075.</div></div><div><h3>Interpretation</h3><div>For the majority of bacterium–antibiotic combinations, the main AMR association was from primary care to hospital settings. These results underscore the importance of antibiotic stewardship at the community level.</div></div><div><h3>Funding</h3><div>ISIS-AR is supported by the <span>Ministry of Health, Welfare and Sport</span> of the Netherlands and the first author by the <span>Central University of Ecuador</span> to follow a PhD program in <span>Erasmus MC</span>.</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"50 ","pages":"Article 101197"},"PeriodicalIF":13.6,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11755011/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143029864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancing paediatric allergy care: key findings from the largest trial of house dust mite sublingual immunotherapy-tablets in children","authors":"Ann-Marie Malby Schoos ,&nbsp;Bo Chawes","doi":"10.1016/j.lanepe.2024.101167","DOIUrl":"10.1016/j.lanepe.2024.101167","url":null,"abstract":"","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"48 ","pages":"Article 101167"},"PeriodicalIF":13.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11699288/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142932975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of disease-modifying therapies on pregnancy outcomes in multiple sclerosis: a prospective cohort study from the German multiple sclerosis and pregnancy registry","authors":"Nadine Bast ,&nbsp;Karen Dost-Kovalsky ,&nbsp;Sabrina Haben ,&nbsp;Natalia Friedmann ,&nbsp;Laura Witt ,&nbsp;Theresa Oganowski ,&nbsp;Ralf Gold ,&nbsp;Sandra Thiel ,&nbsp;Kerstin Hellwig","doi":"10.1016/j.lanepe.2024.101137","DOIUrl":"10.1016/j.lanepe.2024.101137","url":null,"abstract":"<div><h3>Background</h3><div>In recent decades, relapsing remitting multiple sclerosis (MS) became more treatable through new disease-modifying therapies (DMTs). Identifying safe treatments with minimal fetal risks for family planning is needed.</div></div><div><h3>Methods</h3><div>In this prospective cohort from the German MS and Pregnancy Registry (DMSKW), we analyzed pregnancy and neonatal outcomes in MS-patients using descriptive statistics and logistic/linear regression models to compare DMT-exposed pregnancies to DMT-unexposed pregnancies.</div></div><div><h3>Findings</h3><div>In 2885 DMT-exposed and 837 DMT-unexposed pregnancies, exposure was not associated with spontaneous abortions, preterm births or major congenital anomalies (MCAs). Severe infections were rare, but more frequent in the Fumarates-group (11/395: 2.8% vs. 8/837 unexposed-group: 1.0%, p-value: 0.03). Antibiotic-use was associated with 2nd-trimester (OR: 2.47, CI: 1.47, 4.05, p-value: &lt;0.001), 3rd-trimester Natalizumab-exposure (OR: 1.75, CI: 1.15, 2.63, p-value: 0.01), and anti-CD20-exposure (OR: 2.16, CI: 1.41, 3.29, p-value: &lt;0.001). Birthweight was significantly reduced in the Sphingosine-1-phosphate-group (β: −132 g, CI: −205, −60, p-value: &lt;0.001), and 3rd-trimester Natalizumab-subgroup (β: −74 g, CI: −138, −9.4, p-value: 0.02). Small for gestational age (SGA) neonates were common in the Sphingosine-1-phospate- (OR: 1.65, CI: 1.07, 2.50, p-value: 0.02) and anti-CD20-group (OR: 1.54, CI: 1.01, 2.32, p-value: 0.04), and also the entire cohort (651/3459: 18.8%), exceeding the general German population rate (10%) (p-value: &lt;0.001).</div></div><div><h3>Interpretation</h3><div>We observed an increased SGA risk, especially following highly-effective DMTs, although the pathomechanisms remain unclear. More research is needed on infection risks and MCAs, perhaps by linking different registries.</div></div><div><h3>Funding</h3><div>The DMSKW is partly supported by <span>Almirall</span>, <span>Biogen</span>, <span>Hexal</span>, <span>Merck</span>, <span>Novartis</span>, <span>Roche</span>, <span>Sanofi Genzyme</span>, <span>Teva Pharma</span> and <span>Viatris</span>.</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"48 ","pages":"Article 101137"},"PeriodicalIF":13.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11732200/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142985370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Physiological versus time based cord clamping in very preterm infants (ABC3): a parallel-group, multicentre, randomised, controlled superiority trial","authors":"Ronny Knol ,&nbsp;Emma Brouwer ,&nbsp;Thomas van den Akker ,&nbsp;Philip L.J. DeKoninck ,&nbsp;Wes Onland ,&nbsp;Marijn J. Vermeulen ,&nbsp;Willem P. de Boode ,&nbsp;Anton H. van Kaam ,&nbsp;Enrico Lopriore ,&nbsp;Irwin K.M. Reiss ,&nbsp;G. Jeroen Hutten ,&nbsp;Sandra A. Prins ,&nbsp;Estelle E.M. Mulder ,&nbsp;Esther J. d’Haens ,&nbsp;Christian V. Hulzebos ,&nbsp;Helene A. Bouma ,&nbsp;Sam J. van Sambeeck ,&nbsp;Hendrik J. Niemarkt ,&nbsp;Mayke E. van der Putten ,&nbsp;Tinta Lebon ,&nbsp;Arjan B. te Pas","doi":"10.1016/j.lanepe.2024.101146","DOIUrl":"10.1016/j.lanepe.2024.101146","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;div&gt;Physiological-based cord clamping (PBCC) in preterm infants is beneficial for cardiovascular transition at birth and may optimize placental transfusion. Whether PBCC can improve clinical outcomes is unknown. The aim of the Aeration, Breathing, Clamping (ABC3) trial was to test whether PBCC results in improved intact survival in very preterm infants.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;The ABC3 trial was a parallel-group, multicentre, randomised, controlled superiority clinical trial conducted in all Dutch tertiary referral centers for perinatal care involving infants born before 30 weeks of gestation. Infants were randomised to either PBCC or time-based delayed cord clamping (TBCC), stratified by gestational age and treatment center. Infants receiving PBCC were stabilised with umbilical cord intact, which was clamped after reaching cardiorespiratory stability (heart rate &gt;100 bpm and SpO2 &gt;85% while supplemental oxygen &lt;40%). In TBCC the cord was clamped after 30–60 s. The primary outcome was survival without major cerebral injury and/or necrotizing enterocolitis. The primary and key secondary analyses were done in both the intention-to-treat and per-protocol populations. The trial was registered with &lt;span&gt;&lt;span&gt;ClinicalTrials.gov&lt;/span&gt;&lt;svg&gt;&lt;path&gt;&lt;/path&gt;&lt;/svg&gt;&lt;/span&gt; (&lt;span&gt;&lt;span&gt;NCT03808051&lt;/span&gt;&lt;svg&gt;&lt;path&gt;&lt;/path&gt;&lt;/svg&gt;&lt;/span&gt;).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Findings&lt;/h3&gt;&lt;div&gt;From January 25, 2019, through October 2, 2022, 669 infants were randomised (median gestational age 27&lt;sup&gt;+5&lt;/sup&gt; weeks (IQR 26&lt;sup&gt;+2&lt;/sup&gt;–28&lt;sup&gt;+6&lt;/sup&gt;)) and included in the intention-to-treat population. Intact survival occurred in 241 of 339 infants (71.1%) after PBCC, compared with 223 of 330 (67.6%) after TBCC (odds ratio 1.18, 95% CI 0.84–1.66; absolute risk difference 3.1 %points, 95% CI −11.0 to 15.8, p = 0.33). Pre-specified subgroup analysis showed 69.9% intact survival in male infants after PBCC, compared with 61.8% after TBCC (odds ratio 2.32, 95% CI 1.42–3.78, p for interaction 0.026). Secondary outcomes showed fewer red blood cell transfusions after PBCC (rate ratio 0.83, 95% CI 0.75–0.92, p = 0.0003), lower incidence of late-onset sepsis (27.4% versus 33.3%, odds ratio 0.77, 95% CI 0.62–0.95, p = 0.013) and lower admission temperature (36.3 °C versus 36.7 °C, mean difference −0.5, 95% CI −0.8 to −0.3, p &lt; 0.0001). Parents were less anxious (Likert scale 1.52 (SD 0.97) versus 2.23 (SD 1.35); p &lt; 0.001) and more content (Likert scale 4.74 (SD 0.75) versus 4.49 (SD 0.97); p &lt; 0.001) after PBCC.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Interpretation&lt;/h3&gt;&lt;div&gt;PBCC in very preterm infants did not increase survival without major cerebral injury or necrotizing enterocolitis compared to TBCC in the entire cohort. A possible beneficial effect in male infants requires confirmation from other trials. PBCC was safe to perform and parents reported more contentment and less anxiety.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Funding&lt;/h3&gt;&lt;div&gt;&lt;span&gt;The Netherlands Organi","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"48 ","pages":"Article 101146"},"PeriodicalIF":13.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11664066/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142883553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Confronting alcohol’s costly toll: why the European region needs clearer, evidence-based policy","authors":"Hans P. Kluge,&nbsp;Gauden Galea,&nbsp;Carina Ferreira-Borges,&nbsp;Catherine Paradis","doi":"10.1016/j.lanepe.2024.101179","DOIUrl":"10.1016/j.lanepe.2024.101179","url":null,"abstract":"","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"48 ","pages":"Article 101179"},"PeriodicalIF":13.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11699214/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142933311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Medical research agency: 5 years of reshaping the clinical trials ecosystem in Poland","authors":"Diana Kitala ,&nbsp;Katarzyna Kaczmarska ,&nbsp;Joanna Kornacka ,&nbsp;Krzysztof Górski ,&nbsp;Elżbieta Bylina ,&nbsp;Karolina Nowak ,&nbsp;Rafał Staszewski ,&nbsp;Zuzanna Nowak-Życzyńska ,&nbsp;Wojciech Fendler","doi":"10.1016/j.lanepe.2024.101175","DOIUrl":"10.1016/j.lanepe.2024.101175","url":null,"abstract":"","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"48 ","pages":"Article 101175"},"PeriodicalIF":13.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11699205/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142933517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"There is more to nutrition and cardiovascular disease than ultra-processing— authors’ reply","authors":"Fernanda Rauber ,&nbsp;Maria Laura da Costa Louzada ,&nbsp;Kiara Chang ,&nbsp;Carlos Augusto Monteiro ,&nbsp;Eszter P. Vamos ,&nbsp;Renata Bertazzi Levy","doi":"10.1016/j.lanepe.2024.101142","DOIUrl":"10.1016/j.lanepe.2024.101142","url":null,"abstract":"","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"48 ","pages":"Article 101142"},"PeriodicalIF":13.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143173229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical characteristics and serological profiles of Lyme disease in children: a 15-year retrospective cohort study in Switzerland","authors":"Beat M. Greiter ,&nbsp;Semjon Sidorov ,&nbsp;Ester Osuna ,&nbsp;Michelle Seiler ,&nbsp;Christa Relly ,&nbsp;Annette Hackenberg ,&nbsp;Isabelle Luchsinger ,&nbsp;Elvira Cannizzaro ,&nbsp;Roland Martin ,&nbsp;Martina Marchesi ,&nbsp;Stefanie von Felten ,&nbsp;Adrian Egli ,&nbsp;Christoph Berger ,&nbsp;Patrick M. Meyer Sauteur","doi":"10.1016/j.lanepe.2024.101143","DOIUrl":"10.1016/j.lanepe.2024.101143","url":null,"abstract":"<div><h3>Background</h3><div>Lyme disease (LD) is caused by <em>Borrelia burgdorferi</em> and is the most common tickborne disease in the northern hemisphere. Although classical characteristics of LD are well-known, the diagnosis and treatment are often delayed. Laboratory diagnosis by serological testing is recommended for most LD manifestations. The objective of this study was to describe clinical characteristics and associated serological profiles in children with LD.</div></div><div><h3>Methods</h3><div>This retrospective cohort study included children aged 0–18 years, diagnosed with LD according to current guidelines at University Children's Hospital Zurich between January 1, 2006 and December 31, 2020. Two-tier serological testing with the <em>recom</em>Well enzyme-linked immunosorbent assay and <em>recom</em>Line Western blot (MIKROGEN Diagnostik, MIKROGEN GmbH, Neuried, Germany) was performed at the Institute of Medical Microbiology, University of Zurich.</div></div><div><h3>Findings</h3><div>In total, 469 children diagnosed with LD were included (median age, 7.9 years); 190 patients (40.5%) with Lyme neuroborreliosis (LNB), 171 (36.5%) patients with skin manifestations (erythema migrans, <em>n</em> = 121; multiple erythema migrans, <em>n</em> = 11; borrelial lymphocytoma, <em>n</em> = 37; and acrodermatitis chronica atrophicans, <em>n</em> = 2), and 108 (23.0%) patients with Lyme arthritis. We observed seasonal variations for patients with skin manifestations and LNB, with high prevalence in May–October, but not for patients with Lyme arthritis. Significant differences between LD manifestation groups were found for age, inflammatory parameters, and specificity and concentration of <em>B. burgdorferi</em>-specific serum antibody responses. We observed distinct patterns of pronounced serum antibody responses against <em>B. burgdorferi</em> antigens in LNB (IgM against VlsE, p41, and OspC) and Lyme arthritis (IgG against p100, VlsE, p58, p41, p39, and p18).</div></div><div><h3>Interpretation</h3><div>Our study is one of the largest and most detailed for children with LD. We present unique findings regarding the differences in clinical characteristics and immune responses between various manifestations of LD in children.</div></div><div><h3>Funding</h3><div>No specific funding to disclose for this study.</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"48 ","pages":"Article 101143"},"PeriodicalIF":13.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11683244/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142907875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How we count matters – infections are a major cause of death among patients with type 2 diabetes","authors":"Henrik Støvring ,&nbsp;Sarah Wild","doi":"10.1016/j.lanepe.2024.101177","DOIUrl":"10.1016/j.lanepe.2024.101177","url":null,"abstract":"","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"48 ","pages":"Article 101177"},"PeriodicalIF":13.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11699254/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142933312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}